[1] |
Yu Y, Jiang XX, Li JC. Biomarker discovery for tuberculosis using metabolomics. Front Mol Biosci, 2023, 20 (10): 1099654. doi:10.3389/fmolb.2023.1099654.
|
[2] |
World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organizaiton, 2022.
|
[3] |
卢春容, 房宏霞, 陆普选, 等. WHO 2021年全球结核病报告:全球与中国关键数据分析. 新发传染病电子杂志, 2021, 6 (4): 368-372. doi:10.19871/j.cnki.xfcrbzz.2021.04.023.
|
[4] |
Zhang Y, Ye J, Hou S, et al. Spatial-temporal analysis of pulmonary tuberculosis in Hubei Province, China, 2011—2021. PloS One, 2023, 18 (2): e0281479. doi:10.1371/journal.pone.0281479.
|
[5] |
Calderwood CJ, Wilson JP, Fielding KL, et al. Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis. PLoS Med, 2021, 18 (4):e1003566. doi:10.1371/journal.pmed.1003566.
|
[6] |
Nandasena S, Senavirathna C, Munasinghe C, et al. Characteristics and sputum conversion of tuberculosis (TB) patients in Kalutara, Sri Lanka. Indian J Tuberc, 2019, 66 (1):76-80. doi:10.1016/j.ijtb.2018.04.008.
pmid: 30797288
|
[7] |
World Health Organization. WHO guidelines on tuberculosis infection prevention and control: 2019 update. WHO Guidelines Approved by the Guidelines Review Committee.Geneva:World Health Organization, 2019.
|
[8] |
张小其, 刘靖元. 259例初治涂阳肺结核患者强化期传染性变化及阴转情况分析. 临床合理用药杂志, 2020, 13(31): 145-147. doi:10.15887/j.cnki.13-1389/r.2020.31.069.
|
[9] |
苏雅星. 延安市初治涂阳肺结核患者治疗2月末痰涂片未转阴的影响因素分析. 延安:延安大学, 2022. doi:10.27438/d.cnki.gyadu.2022.000447.
|
[10] |
阿地力·托乎提. 阿克苏地区初治涂阳肺结核患者转阴时间及影响因素分析. 乌鲁木齐:新疆医科大学, 2020. doi:10.27433/d.cnki.gxyku.2020.000708.
|
[11] |
Khor LA, A Wahid UNI, Ling LL, et al. Prevalence and associated factors of delayed sputum smear conversion in patients treated for smear positive pulmonary tuberculosis: A retrospective follow up study in Sabah, Malaysia. PLoS One, 2023, 18(3): e0282733. doi:10.1371/journal.pone.0282733.
|
[12] |
Asemahagn MA. Sputum smear conversion and associated factors among smear-positive pulmonary tuberculosis patients in East Gojjam Zone, Northwest Ethiopia: a longitudinal study. BMC Pulm Med, 2021, 21(1): 118. doi:10.1186/s12890-021-01483-w.
pmid: 33832466
|
[13] |
Bhatti Z, Khan AH, Sulaiman SAS, et al. Determining the risk factors associated with delayed sputum conversion at the end of the intensive phase among tuberculosis patients. East Mediterr Health J, 2021, 27(8):755-763. doi:10.26719/2021.27.8.755.
pmid: 34486711
|
[14] |
Djouma FN, Noubom M, Ateudjieu J, et al. Delay in sputum smear conversion andoutcomes of smear-positive tuberculosis patients: a retrospective cohort study in Bafoussam, Cameroon. BMC Infect Dis, 2015, 15: 139. doi:10.1186/s12879-015-0876-1.
|
[15] |
Ukwaja KN, Oshi DC, Oshi SN, et al. Profile and treatment outcome of smear-positive TB patients who failed to smear convert after 2 months of treatment in Nigeria. Trans R Soc Trop Med Hyg, 2014, 108 (7): 431-438. doi:10.1093/trstmh/tru070.
|
[16] |
Ruan QL, Yang QL, Sun F, et al. Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China. Clin Microbiol Infect, 2022, 28 (5): 684-689. doi:10.1016/j.cmi.2021.09.022.
|
[17] |
Chaves Torres NM, Quijano Rodríguez JJ, Porras Andrade PS, et al. Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis. PloS One, 2019, 14 (12): e0226507. doi:10.1371/journal.pone.0226507.
|
[18] |
中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09.
|
[19] |
卫生部疾病预防控制局, 卫生部医政司,中国疾病预防控制中心. 中国结核病防治规划实施工作指南(2008年版). 北京: 中国协和医科大学出版社, 2009.
|
[20] |
陈余兴, 王贵. 高龄老年骨科手术患者术后低蛋白血症风险因素及预测模型. 中国老年学杂志, 2022, 42 (1): 55-59. doi:10.3969/j.issn.1005-9202.2022.01.016.
|
[21] |
闫旭, 王文静, 赵丹彤. 酒精性肝硬化患者贫血特征分析. 临床肝胆病杂志, 2022, 38(8):1806-1812. doi:10.3969/j.issn.1001-5256.2022.08.017.
|
[22] |
Li L, Ma CJ, Chang YF, et al. The characteristics of overseas imported COVID-19 cases and the effectiveness of screening strategies in Beijing, China. BMC Infect Dis, 2022, 2 (1): 59. doi:10.1186/s12879-021-06998-5.
|
[23] |
张曾航, 郭晓雷, 殷召雪, 等. 血压在体质指数与心血管疾病发生风险间的中介效应. 中国公共卫生, 2023, 39(3):330-334. doi:10.11847/zgggws1140656.
|
[24] |
Siddiqui AN, Khayyam KU, Sharma M. Effect of diabetes mellitus on tuberculosis treatment outcome and adverse reactions in patients receiving directly observed treatment strategy in india: a prospective study. Biomed Res Int, 2016, 2016: 7273935. doi:10.1155/2016/7273935.
|
[25] |
Ibrahim MN, Nik Husain NR, Daud A, et al. Epidemiology and risk factors of delayed sputum smear conversion in malaysian aborigines with smear-positive pulmonary tuberculosis. Int J Environ Res Public Health, 2022, 19 (4): 2365. doi:10.3390/ijerph19042365.
|
[26] |
Luo PP, Wu L, Liu F, et al. Clinical efficacy of chemotherapy regimen combined with levofloxacin in patients with pulmonary tuberculosis complicated with type-2 diabetes. Pak J Med Sci, 2023, 39 (2): 444-449. doi:10.12669/pjms.39.2.6364.
|
[27] |
Ssekamatte P, Sande OJ, van Crevel R, et al. Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility. Front Immunol, 2023, 14: 1122255. doi:10.3389/fimmu.2023.1122255.
|
[28] |
Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis (Edinb), 2015, 95 (1): 54-59. doi:10.1016/j.tube.2014.10.013.
|
[29] |
Alfarisi O, Mave V, Gaikwad S, et al. Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother, 2018, 62 (11): e01383-18. doi:10.1128/AAC.01383-18.
|
[30] |
Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis, 2013, 13 (5): 436-448. doi:10.1016/S1473-3099(13)70015-X.
pmid: 23531392
|
[31] |
Mouton JP, Mehta U, Parrish AG, et al. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. Br J Clin Pharmacol, 2015, 80 (4): 818-826. doi:10.1111/bcp.12567.
pmid: 25475751
|
[32] |
Santos JA, Leite A, Soares P, et al. Delayed diagnosis of active pulmonary tuberculosis-potential risk factors for patient and healthcare delays in Portugal. BMC Public Health, 2021, 21 (1): 2178. doi:10.1186/s12889-021-12245-y.
|
[33] |
He M, Yang X, Zhang Z, et al. Impaired pulmonary function and associated factors in the elderly with tuberculosis on admission: a preliminary report. BMC Infect Dis, 2023, 23 (1): 251. doi:10.1186/s12879-023-08183-2.
pmid: 37076819
|
[34] |
Martin-Higuera MC, Rivas G, Rolo M, et al. Xpert MTB/RIF Ultra CT value provides a rapid measure of sputum bacillary burden and predicts smear status in patients with pulmonary tuberculosis. Sci Rep, 2023, 13 (1): 1591. doi:10.1038/s41598-023-28869-6.
pmid: 36709214
|
[35] |
Perrin FM, Woodward N, Phillips PP, et al. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. Int J Tuberc Lung Dis, 2010, 14 (12): 1596-1602.
pmid: 21144246
|
[36] |
Palaci M, Dietze R, Hadad DJ, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol, 2007, 45 (12): 4064-4066. doi:10.1128/JCM.01780-07.
pmid: 17928422
|
[37] |
Matsuoka S, Uchiyama K, Shima H, et al. Relationship between CT findings of pulmonary tuberculosis and the number of acid-fast bacilli on sputum smears. Clin Imaging, 2004, 28 (2): 119-123. doi:10.1016/S0899-7071(03)00148-7.
|
[38] |
Kempker RR, Rabin AS, Nikolaishvili K, et al. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis, 2012, 54 (6): e51-54. doi:10.1093/cid/cir904.
|
[39] |
Sinha P, Davis J, Saag L, et al. Undernutrition and tuberculosis: public health implications. J Infect Dis, 2019, 219 (9):1356-1363. doi:10.1093/infdis/jiy675.
pmid: 30476125
|
[40] |
Koethe JR, von Reyn CF. Protein-calorie malnutrition, macronutrient supplements, and tuberculosis. Int J Tuberc Lung Dis, 2016, 20 (7): 857-863. doi:10.5588/ijtld.15.0936.
pmid: 27287634
|
[41] |
Alghamdi WA, Al-Shaer MH, Peloquin CA. Protein binding of first-line antituberculosis drugs Antimicrob Agents Chemother, 2018, 62 (7): e00641-18. doi:10.1128/AAC.00641-18.
|
[42] |
Justine M, Yeconia A, Nicodemu I, et al. Pharmacokinetics of first-line drugs among children with tuberculosis in rural tanzania. J Pediatric Infect Dis Soc, 2020, 9 (1): 14-20. doi:10.1093/jpids/piy106.
pmid: 30395239
|
[43] |
Nagu TJ, Spiegelman D, Hertzmark E, et al. Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmonary tuberculosis patients in Dar-es-Salaam, Tanzania PloS One, 2014, 9 (3): e91229. doi:10.1371/journal.pone.0091229.
|
[44] |
Luo M, Liu M, Wu X, et al. Impact of anemia on prognosis in tuberculosis patients. Ann Transl Med, 2022, 10 (6): 329. doi:10.21037/atm-22-679.
pmid: 35433932
|
[45] |
Abaynew Y, Ali A, Taye G, et al. Prevalence and types of anemia among people with tuberculosis in Africa: a systematic review and meta-analysis. Sci Rep, 2023, 13 (1): 5385. doi:10.1038/s41598-023-32609-1.
pmid: 37012387
|
[46] |
Isanaka S, Aboud S, Mugusi F, et al. Iron status predicts treatment failure and mortality in tuberculosis patients: a prospective cohort study from Dares Salaam, Tanzania. PloS One, 2012, 7 (5): e37350. doi:10.1371/journal.pone.0037350.
|
[47] |
Ashenafi S, Bekele A, Aseffa G, et al. Anemia is a strong predictor of wasting, disease severity, and progression, in clinical tuberculosis (TB). Nutrients, 2022, 14 (16):3318. doi:10.3390/nu14163318.
|
[48] |
Minardi ML, Fato I, Di Gennaro F, et al. Common and rare hematological manifestations and adverse drug events during treatment of active TB: a state of art. Microorganisms, 2021, 9 (7): 1477. doi:10.3390/microorganisms9071477.
|